Teva Pharmaceutical Industries (NYSE:TEVA) received a $11.00 target price from stock analysts at Royal Bank Of Canada in a research report issued to clients and investors on Wednesday. The brokerage presently has a "sell" rating on the stock. Royal Bank Of Canada’s price objective suggests a potential downside of 25.58% from the stock’s previous close.

A number of other analysts also recently weighed in on TEVA. Mizuho reiterated a "hold" rating and issued a $30.00 price target on shares of Teva Pharmaceutical Industries in a research report on Wednesday, August 2nd. Oppenheimer downgraded shares of Teva Pharmaceutical Industries from an "outperform" rating to a "market perform" rating and set a $41.00 target price on the stock. in a report on Thursday, August 3rd. Credit Suisse Group set a $39.00 target price on shares of Teva Pharmaceutical Industries and gave the stock a "buy" rating in a report on Thursday, August 3rd. UBS downgraded shares of Teva Pharmaceutical Industries from an "outperform" rating to a "market perform" rating in a report on Thursday, August 3rd. Finally, CIBC restated a "market perform" rating on shares of Teva Pharmaceutical Industries in a report on Thursday, August 3rd. Seven research analysts have rated the stock with a sell rating, seventeen have issued a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of "Hold" and a consensus price target of $21.65.